Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 11, 2006
Labd-14-ene-8,13-diol (sclareol) induces cell cycle arrest and apoptosis in human breast cancer cells and enhances the activity of anticancer drugsK Dimas, M Papadaki, C Tsimplouli, et al.
Cancer Research|December 15, 1991
Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cellsS Kharbanda, E Rubin, H Gunji, et al.
Oncology Research|January 1, 1993
Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenograftsP Pantazis, A J Kozielski, D M Vardeman, et al.
Annals of the New York Academy of Sciences|December 13, 1996
Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agentsE A Natelson, B C Giovanella, C F Verschraegen, et al.
Oncogene|August 30, 2000
Susceptibility to apoptosis is restored in human leukemia HCW-2 cells following induction and stabilization of the apoptotic effector BakD Chatterjee, P Pantazis, G Li, et al.
Chemotherapy|April 29, 2006
Differential susceptibility to etoposide in clones derived from a human ovarian cancer cell lineK V Balan, N M Sitaras, K Dimas, et al.
The Journal of Biological Chemistry|August 22, 2001
A Fas-associated death domain protein-dependent mechanism mediates the apoptotic action of non-steroidal anti-inflammatory drugs in the human leukemic Jurkat cell lineZ Han, P Pantazis, J H Wyche, et al.
Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research|October 28, 1997
Monocytic differentiation of HL-60 promyelocytic leukemia cells correlates with the induction of Bcl-xLD Chatterjee, Z Han, J Mendoza, et al.
Anticancer Research|September 1, 1995
Development of human leukemia U-937 cell sublines resistant to doxorubicin: induction of differentiation and altered sensitivities to topoisomerase-directed drugsP Pantazis, A Dejesus, J Early, et al.
International Journal of Oncology|April 14, 1999
A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancerJ S Stehlin, B C Giovanella, E A Natelson, et al.
Pageof 13